【摘要】：Human glioma is the most common and aggressive primary brain cancer with mean patient survival.Traditional radiotherapy and chemotherapy aim at tumor cells,but disregard glioma stem cells,which play a crucial role in tumorigenesis,development,metastasis and recurrence,with strongly proliferative and tumorigenic activity.Boron neutron capture therapy(BNCT) is a unique dose-dependent tumor-selective radiotherapy based on thermal-neutron irradiation treatment to the cells enriched with boron(10B),which produces short range and significant killing effectiveness.The success of BNCT is dependent on the absolute amount of boron in every tumor cell and the boron concentration ratios of tumor/blood and tumor/normal tissue.To study the possibility of applying BNCT to the damage of glioma stem/progenitor cells,cells for boron uptake and animal model for boron biodistribution measurements were developed.Selective absorption of BPA appeared in glioma stem/progenitor cells,although the dose of boron in every cell was less than that in differentiated glioma cell.The retention dosage of boron in glioma stem/progenitor cells maintained 66% residual after BPA withdrawed 24h.The boron concentration ratios of tumor-to-normal brain and tumor-to-blood in glioma stem/progenitor cells implanted mice was higher than 2.5:1 and the absolute amount reached peak in tumor at 2.5h after 500mg/kg BPA administration.This study shows that boron biodistribution from BPA was no statistical differences in glioma stem/progenitor cells xenograft mice comparing to differentiated glioma cell xenograft mice,but it showed lower accumulation and longer retention in vitro.